Pyxis Oncology, Inc.
NASDAQ:PYXS · NASDAQ Global Select
+$0.11 today
Vol 0.63M · Avg 0.50M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:PYXS · Revenue to Net Income
Key Ratios
Analysis
$13.9M of revenue converted into -$81.7M of net income for the selected period. Gross margin is 51.0% and net margin is -203.7%, showing how much revenue survives after costs and taxes. EPS is $-1.31, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.9M -14.2% | $16.1M | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $2.4M +402.7% | $475.0K | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $11.5M -26.8% | $15.7M | $0 | $0 | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | 82.8% -14.3pp | 97.1% | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $73.7M +25.4% | $58.7M +18.5% | $49.6M -42.4% | $86.1M +68.7% | $51.1M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $22.2M -12.7% | $25.4M -22.0% | $32.6M -12.7% | $37.4M +100.1% | $18.7M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $95.9M -8.8% | $105.1M +27.9% | $82.2M -33.4% | $123.5M +77.1% | $69.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $4.5M +51.3% | $3.0M +54.7% | $1.9M +171.8% | $709.0K +9.6% | $647.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$73.7M -12.5% | -$65.5M +8.8% | -$71.9M +40.1% | -$120.0M -59.3% | -$75.3M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -532.0% -126.2pp | -405.8% | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$84.4M +5.6% | -$89.5M -8.8% | -$82.2M +33.4% | -$123.5M -77.1% | -$69.7M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -609.2% -55.1pp | -554.1% | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $3.6M -48.7% | $7.0M +6.2% | $6.6M +139.9% | $2.8M +11917.4% | $23.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $6.2M -37.9% | $10.0M +18.5% | $8.4M +204.1% | $2.8M +144.2% | -$6.3M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$78.2M +1.6% | -$79.5M -7.7% | -$73.8M +38.9% | -$120.7M -58.9% | -$76.0M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -564.5% -72.2pp | -492.4% | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $1.4M +164.0% | -$2.2M | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$79.6M -3.0% | -$77.3M -4.8% | -$73.8M +38.9% | -$120.7M -58.9% | -$76.0M | $4.9B | $4.8B | $4.7B |
| Net Margin | -574.5% -95.6pp | -478.9% | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 +3.0% | -$1 +28.6% | -$2 +48.2% | -$4 -41.1% | -$3 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 +3.0% | -$1 +28.6% | -$2 +48.2% | -$4 -41.1% | -$3 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $62.1M +6.3% | $58.4M +46.5% | $39.9M +20.8% | $33.0M +2.5% | $32.2M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $62.1M +6.3% | $58.4M +46.5% | $39.9M +20.8% | $33.0M +2.5% | $32.2M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$346.92M
Enanta Pharmaceuticals, Inc.
NASDAQ:ENTA
$293.50M
Foghorn Therapeutics Inc.
NASDAQ:FHTX
$242.49M
Zura Bio Limited
NASDAQ:ZURA
$241.23M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$224.47M
Immuneering Corporation
NASDAQ:IMRX
$159.68M
Caribou Biosciences, Inc.
NASDAQ:CRBU
$159.67M
Humacyte, Inc.
NASDAQ:HUMA
$156.59M
Tenaya Therapeutics, Inc.
NASDAQ:TNYA
$117.84M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does PYXS generate?
Pyxis Oncology, Inc. (PYXS) reported $13.86M of revenue in fiscal 2025.
Is PYXS profitable?
Pyxis Oncology, Inc. (PYXS) reported -$79,621,000.00 of net income, with a net margin of -574.5%.
Explore More
Continue the stock analysis
Jump to another research area for this company.